A new report from FiercePharma details the most expensive #RxDrugs in the U.S. in 2025 – providing an opportunity to analyze the gap between #BigPharma’s out-of-control prices and clinical value for patients. See how #BigPharma’s prices far exceed @ICER’s fair price estimates:

📈#BigPharma continues to set out-of-control prices, especially on newly launched brand name products. Get a dose of reality on Big Pharma’s egregious prices for their highest priced products:

📈Johnson & Johnson once again outperforms Wall Street analysts’ revenue expectations while repeatedly hiking prices on brand name drugs and using anti-competitive tactics to undermine competition from more affordable alternatives. Get the latest: csrxp.org/big-pharma-ear…

#BigPharma giant Roche reported big-time Q2 earnings following continued price hikes on their blockbuster drugs. Read more:

ICYMI: GSK’s Q2 earnings results beat Wall Street forecasts, fueled by price hikes. Get the facts:

AstraZeneca and GSK surpassed Wall Street’s expectations for Q2, driven by egregious prescription drug price hikes and a playbook of blocking competition. See the full breakdown:

ICYMI: A recent study in JAMA Health Forum found Big Pharma’s patent thickets on just four brand name drugs cost American patients more than $3.5 BILLION in two years. See the findings:

DOSE OF REALITY: Big Pharma price gouges American patients by gaming the U.S. patent system to block competition from more affordable alternatives. Read more on a new study on the cost of Big Pharma’s patent abuse:

NEW: Reporting from AAM & IQVIA Institute found that generic and biosimilar medications saved American patients and the U.S. health care system $467 BILLION in 2024 alone by providing competition to brand name drugs. Learn more:

Big Pharma deploys a suite of tactics designed to game the U.S. patent system – extending monopolies over their biggest money-makers & blocking competition from generics & biosimilars. More on how competition produces savings & how bipartisan solutions will foster competition:

This morning, Energy and Commerce Committee is holding a markup on bipartisan legislation that would increase transparency in generic drug applications – reforming Q1/Q2 sameness requirements from the U.S. FDA that Big Pharma abuses to extend exclusivity. Learn more:

ICYMI: U.S. FDA commissioner Marty Makary MD, MPH highlights how Big Pharma’s staggering spending on advertising directly targeting consumers misleads American patients and increases prescription drug spending – calling for reforms to hold them accountable. Learn more:

New analysis demonstrates how Big Pharma promptly admitted more than 40 patents on brand name Rx drugs were shams after the most recent round of challenges from the FTC, underscoring the scale of Big Pharma’s patent thickets. More on Big Pharma’s anti-competitive tactics:

Big Pharma games the system to block competition from more affordable alternatives to brand name drugs by abusing a process known as “Q1/Q2 sameness." More on how lawmakers are working to advance bipartisan solutions to crack down on Big Pharma’s anti-competitive tactics:

🔊Energy and Commerce Committee/Energy & Commerce Democrats advanced bipartisan legislation last week that would increase transparency in generic drug applications – reforming U.S. FDA Q1/Q2 sameness requirements that Big Pharma abuses to extend exclusivity. Learn more about the committee markup:

ICYMI: In last week’s Energy and Commerce Committee/Energy & Commerce Democrats hearing, lawmakers highlighted the importance of promoting competition – cracking down on anti-competitive tactics used by Big Pharma to extend exclusivity that keeps drug prices HIGH. Hear what they had to say on the issue:

Big Pharma loves to point a finger at others to distract from brand name drug companies’ rapidly rising launch prices, unjustified price hikes outpacing inflation and anti-competitive tactics that extend monopolies and block competition. Read more:

Ahead of a hearing on The Patent Eligibility Restoration Act (PERA), we urge lawmakers to reject this Big Pharma-backed proposal and instead build on bipartisan progress to foster greater competition in the prescription drug market. Read our full statement:

Get a Second Opinion on Big Pharma’s latest rerun of its deflection playbook, filled with empty promises and grand pledges meant to deflect responsibility and dodge accountability for high prescription drug prices →

Big Pharma’s egregious abuse of the patent system enables them to set out-of-control launch prices on their products, repeatedly hike prices and block competition. PERA would further enable Big Pharma’s patent abuse. Learn more: